TRB (T Cell Receptor Beta Locus)

Patients with positive TCRγ gene rearrangement are more likely to develop STAT3 gene mutation. These characteristics may be helpful in the differential diagnosis of T-LGLL.

Multivariate analysis identified RNC (OR:0.590;P = 0.048) as the sole independent influencing factor (P < 0.05). RNC is an independent influencing factor for the development of T-LGLL-PRCA.

Finally, we show that high expression of PD-1 on circulating CD4+ T cells is an independent prognostic factor for poor survival in this patient group. This work suggests that MPE T cell phenotypes differ from those in circulation, with blood-based T cell subsets more sensitive predictors of outcome in this study.

Given the patient's age and tumor location, we administered a reduced dose of DeVIC, followed by radiotherapy, achieving partial remission. This case expands the spectrum of EBV-associated T-cell lymphomas and highlights the need for additional cases to refine the classification and management.

In anti PD-1-refractory R/M HNSCC, SBRT with pembrolizumab was safe and feasible, suggesting activity when all progressing lesions were treated. Immune profiling describes pre-existing memory T and B cell phenotypes that appear to correlate with treatment benefit. These findings support further study and clinical use of comprehensive SBRT plus PD-1 blockade in this hard-to-treat population.

In addition, four out of five clones exhibited upregulated transcription of IL-2 in the salivary glands of T/B cell-deficient RAG2-/- mice, suggesting that autoreactive T cells were enriched in the DP T cell population of SATB1cKO mice. These results suggest that unusual DP T cells in SATB1cKO mice may be involved in autoimmune pathogenesis in SATB1cKO mice.

Notably, trastuzumab was associated with increased clonality and reduced diversity in HER2-enriched tumors, but not in Luminal B2. Lower TCR richness in post-treatment blood samples was associated with patients achieving pathologic complete response in the neoadjuvant setting. This study provides comprehensive circulating TCR repertoire metric profiles across the heterogeneous population of breast cancer patients.

Transcriptomics further reveal that AMPK remodels metabolic pathways to augment oxidative injury and energy crisis, facilitating apoptosis. Notably, thymotoxicity persists even at subtherapeutic doses (25 mg/kg), challenging metformin's indiscriminate use in non-diabetic populations due to risks to central immune homeostasis.

Furthermore, there was a notable difference in the usage frequency of TCRβ chain variable/joining gene segments among the different radiation dose groups. The present study demonstrated that RT and immunotherapy may alter the TCR repertoire owing to their effects on HSCs.

Despite containing SLL deposits, the harvested melanoma produced a CD8+ T cell-predominant tumor-reactive TIL infusion product containing stem-like CD39negCD69neg CD8+ T cells. A strong overlap (60%) in the TCRβ sequences between this infusion product and peripheral blood mononuclear cells collected at the 9-month follow-up visit was evidence of long-term persistence of TIL in this patient.

We report the first EBV-negative human type I NKT cell line, NKT617, which offers significant potential for studying NKT cell development and advancing chimeric antigen receptor based therapies. This cell line serves as a valuable tool for exploring NKT cell biology and developing targeted immunotherapies.

Co-culture with TMG-expressing APCs revealed two functional neoantigen-TCR pairs validated by peptide assays (EC50: 10-9.2-10-6.7 M). Collectively, NeoPAIR-T streamlines neoantigen-TCR identification for vaccine and TCR-T applications.